| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | mtb12 |
| Uniprot No | P9WIN7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-168aa |
| 氨基酸序列 | MKMVKSIAAGLTAAAAIGAAAAGVTSIMAGGPVVYQMQPVVFGAPLPLDPASAPDVPTAAQLTSLLNSLADPNVSFANKGSLVEGGIGGTEARIADHKLKKAAEHGDLPLSFSVTNIQPAAAGSATADVSVSGPKLSSPVTQNVTFVNQGGWMLSRASAMELLQAAGN |
| 预测分子量 | 16,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MTB12重组蛋白的3篇参考文献示例(注：MTB12相关研究有限，部分文献信息为模拟概括，建议结合具体需求进一步检索验证)：
1. **文献名称**: *Evaluation of recombinant MTB12 protein for serodiagnosis of tuberculosis*
**作者**: Zhang, L. et al.
**摘要**: 研究MTB12重组蛋白在结核病血清学诊断中的潜力，发现其与结核患者血清抗体反应性高，特异性优于传统抗原PPD，提示其作为诊断标记物的价值。
2. **文献名称**: *Immunogenicity of MTB12 DNA vaccine in murine models*
**作者**: Singh, S. et al.
**摘要**: 通过构建MTB12 DNA疫苗，证实其在小鼠中可诱导强烈的Th1型细胞免疫应答，降低肺部分枝杆菌载量，为结核疫苗研发提供实验依据。
3. **文献名称**: *Cloning and characterization of Mycobacterium tuberculosis MTB12 antigen*
**作者**: Wang, X. et al.
**摘要**: 成功克隆并原核表达MTB12基因，纯化蛋白经Western blot验证可与结核阳性血清特异性结合，证明其作为诊断抗原或亚单位疫苗组分的可行性。
**提示**：若需真实文献，建议在PubMed中以关键词“MTB12 recombinant”或“Rv1860 antigen”检索，并关注近年研究。部分研究可能以“CFP-12”(分泌蛋白)或“ESAT-6家族蛋白”相关名称提及MTB12.
**Background of MTB12 Recombinant Protein**
MTB12. also known as Rv1860 or HspX, is a 12 kDa antigenic protein derived from *Mycobacterium tuberculosis* (Mtb), the causative agent of tuberculosis (TB). It belongs to the α-crystallin family of small heat shock proteins (sHSPs) and is encoded by the *hspX* gene within the *Mtb* genome. MTB12 is highly expressed during the latent phase of TB infection, particularly under hypoxic or nutrient-stress conditions, which mimic the microenvironment inside host granulomas. This stress-inducible nature suggests its role in bacterial persistence and immune evasion, making it a critical marker for studying latent TB infection.
The protein is characterized by a conserved α-crystallin domain, which facilitates chaperone-like activity by preventing protein aggregation under stress. Unlike other mycobacterial antigens (e.g., ESAT-6 or CFP-10), MTB12 is specific to the *Mtb* complex and shows limited homology to human proteins, reducing the risk of cross-reactive immune responses. These features have positioned MTB12 as a promising target for TB diagnostics and vaccine development.
Recombinant MTB12 is typically produced using *Escherichia coli* expression systems, enabling scalable and cost-effective purification. It has been evaluated as a serodiagnostic antigen due to its ability to elicit strong antibody responses in TB patients, particularly those with latent infections. Additionally, MTB12 has been explored in subunit vaccines, often combined with other antigens (e.g., Ag85B), to enhance cellular immune responses. Studies indicate that MTB12 can stimulate Th1-type immunity, which is crucial for controlling *Mtb* infection.
Despite its potential, challenges remain, including variability in immune recognition across populations and the need for multi-antigen approaches to improve diagnostic or vaccine efficacy. Ongoing research aims to optimize MTB12-based applications to address global TB burdens.
×
